Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence.
The role of a viral gene product in evasion of the host immune response was investigated. The antibody-dependent complement-enhanced neutralization of vaccinia virus infectivity was prevented by the culture medium from vaccinia virus-infected cells. The vaccinia virus complement-control protein (VCP) was identified as the secreted product of vaccinia virus gene C21L and has homology to a group of eukaryotic genes encoding regulators of complement activation. Thus, the culture medium from cells infected with a C21L deletion mutant was VCP deficient and had little or no effect on antibody-dependent complement-enhanced neutralization. In addition, the anticomplement effect was associated with the C21L-encoded protein partially purified from the medium of cells infected with wild-type virus. Antibody-dependent, complement-enhanced neutralization of vaccinia virus occurred with a complement source that was deficient in the classical pathway complement component C4 and required the alternative pathway complement factor B. Furthermore, the presence of VCP abrogated the complement-enhanced neutralization in C4-deficient serum. Together with previous hemolysis data, the present result suggests that VCP can inhibit both the classical and alternative pathways of complement activation. Skin lesions caused by the C21L deletion mutant were smaller than those caused by wild-type virus, demonstrating an important role for VCP in virulence. The C21L deletion mutant also was attenuated in C4-deficient guinea pigs, consistent with in vitro studies. Vaccinia virus appears to have acquired the ability to regulate the complement cascade for the purpose of evading the host immune response.
Isaacs
S N
SN
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Kotwal
G J
GJ
Moss
B
B
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology*; D003181:Complement C4 / Q000502:physiology; D011415:Complement Factor B / Q000502:physiology; D003169:Complement Inactivator Proteins; D003170:Complement Pathway, Alternative; D004252:DNA Mutational Analysis; D006168:Guinea Pigs; D009500:Neutralization Tests; D014616:Vaccinia virus / Q000276:immunology / Q000472:pathogenicity*; D014764:Viral Proteins / Q000276:immunology*
D000914:Antibodies, Viral; D003181:Complement C4; D003169:Complement Inactivator Proteins; D014764:Viral Proteins; D011415:Complement Factor B